VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Matulonis Discusses Maintenance in Ovarian Cancer

Ursula A. Matulonis, MD
Published: Wednesday, Apr 26, 2017



Ursula A. Matulonis, MD, professor of Medicine, Harvard Medical School, medical director of Gynecologic Oncology, Dana-Farber Cancer Institute, discusses maintenance therapy in ovarian cancer.

Ovarian cancer has many subgroups, says Matulonis, and successes in therapies such as PARP inhibitors can be attributed to the identification of these more specific populations.

In patients with low-grade serous cancer, aromatase inhibitors as maintenance therapy after platinum-based chemotherapy have shown an improvement in progression-free survival.
 


Ursula A. Matulonis, MD, professor of Medicine, Harvard Medical School, medical director of Gynecologic Oncology, Dana-Farber Cancer Institute, discusses maintenance therapy in ovarian cancer.

Ovarian cancer has many subgroups, says Matulonis, and successes in therapies such as PARP inhibitors can be attributed to the identification of these more specific populations.

In patients with low-grade serous cancer, aromatase inhibitors as maintenance therapy after platinum-based chemotherapy have shown an improvement in progression-free survival.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Expert Perspectives to Incorporate Evidence on PARP Inhibitors into Practice and Optimize the Medical Management of Ovarian CancerOct 31, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x